Cargando…

Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil

BACKGROUND/PURPOSE: The relationship between liver injury and mortality remains unclear in patients with COVID-19. We aimed to evaluate the prognostic value of aminotransferases levels at hospital admission to predict mortality in patients with COVID-19. METHODS AND RESULTS: This prospective study i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozzobon, Fernanda Manhães, Perazzo, Hugo, Bozza, Fernando Augusto, Rodrigues, Rosana Souza, de Mello Perez, Renata, Chindamo, Maria Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857099/
https://www.ncbi.nlm.nih.gov/pubmed/33534084
http://dx.doi.org/10.1007/s12072-021-10141-6
_version_ 1783646379337318400
author Pozzobon, Fernanda Manhães
Perazzo, Hugo
Bozza, Fernando Augusto
Rodrigues, Rosana Souza
de Mello Perez, Renata
Chindamo, Maria Chiara
author_facet Pozzobon, Fernanda Manhães
Perazzo, Hugo
Bozza, Fernando Augusto
Rodrigues, Rosana Souza
de Mello Perez, Renata
Chindamo, Maria Chiara
author_sort Pozzobon, Fernanda Manhães
collection PubMed
description BACKGROUND/PURPOSE: The relationship between liver injury and mortality remains unclear in patients with COVID-19. We aimed to evaluate the prognostic value of aminotransferases levels at hospital admission to predict mortality in patients with COVID-19. METHODS AND RESULTS: This prospective study included 406 patients [57% male, aged 56 years] with COVID-19 hospitalized in 26 centers in Brazil. Overall, 36.7% (95% CI 32.1–41.5) presented at admission with severe disease requiring respiratory support. The prevalence of elevated ALT and AST levels at admission [> 2 × ULN] was 14.0% (95% CI 11.0–17.8) and 12.9% (95% CI 10.0–16.6), respectively. Sixty-two patients [15.3% (95% CI 12.1–19.1)] died during hospitalization and the overall mortality rate was 13.4 (10.5–17.2) deaths per 1000 persons-years. The 15-day-overall survival (95% CI) was significantly lower in patients with ALT levels ≥ 2 × ULN compared to those with ALT < 2 × ULN [67.1% (48.4–80.2) vs 83.4% (76.1–88.6), p = 0.001] and in those with AST levels ≥ 2 × ULN compared to those with AST < 2 × ULN [61.5% (44.7–74.6) vs 84.2% (76.5–89.5), p < 0.001]. The presence of elevated aminotransferases levels at hospital admission significantly increased the risk of in-hospital all-cause mortality adjusted for age-and-sex. Those findings were present in the subgroup of critically ill patients already admitted in need of respiratory support (n = 149), but not in patients without that requirement at admission (n = 257). CONCLUSIONS: Elevated aminotransferases at hospital admission predicted in-hospital all-cause mortality in patients with COVID-19, especially in those with severe disease. Measurement of transaminases levels at hospital admission should be integrated to the care of patients with COVID-19 as an auxiliary strategy to identify patients at higher death risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10141-6.
format Online
Article
Text
id pubmed-7857099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-78570992021-02-04 Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil Pozzobon, Fernanda Manhães Perazzo, Hugo Bozza, Fernando Augusto Rodrigues, Rosana Souza de Mello Perez, Renata Chindamo, Maria Chiara Hepatol Int Original Article BACKGROUND/PURPOSE: The relationship between liver injury and mortality remains unclear in patients with COVID-19. We aimed to evaluate the prognostic value of aminotransferases levels at hospital admission to predict mortality in patients with COVID-19. METHODS AND RESULTS: This prospective study included 406 patients [57% male, aged 56 years] with COVID-19 hospitalized in 26 centers in Brazil. Overall, 36.7% (95% CI 32.1–41.5) presented at admission with severe disease requiring respiratory support. The prevalence of elevated ALT and AST levels at admission [> 2 × ULN] was 14.0% (95% CI 11.0–17.8) and 12.9% (95% CI 10.0–16.6), respectively. Sixty-two patients [15.3% (95% CI 12.1–19.1)] died during hospitalization and the overall mortality rate was 13.4 (10.5–17.2) deaths per 1000 persons-years. The 15-day-overall survival (95% CI) was significantly lower in patients with ALT levels ≥ 2 × ULN compared to those with ALT < 2 × ULN [67.1% (48.4–80.2) vs 83.4% (76.1–88.6), p = 0.001] and in those with AST levels ≥ 2 × ULN compared to those with AST < 2 × ULN [61.5% (44.7–74.6) vs 84.2% (76.5–89.5), p < 0.001]. The presence of elevated aminotransferases levels at hospital admission significantly increased the risk of in-hospital all-cause mortality adjusted for age-and-sex. Those findings were present in the subgroup of critically ill patients already admitted in need of respiratory support (n = 149), but not in patients without that requirement at admission (n = 257). CONCLUSIONS: Elevated aminotransferases at hospital admission predicted in-hospital all-cause mortality in patients with COVID-19, especially in those with severe disease. Measurement of transaminases levels at hospital admission should be integrated to the care of patients with COVID-19 as an auxiliary strategy to identify patients at higher death risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10141-6. Springer India 2021-02-03 /pmc/articles/PMC7857099/ /pubmed/33534084 http://dx.doi.org/10.1007/s12072-021-10141-6 Text en © Asian Pacific Association for the Study of the Liver 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Pozzobon, Fernanda Manhães
Perazzo, Hugo
Bozza, Fernando Augusto
Rodrigues, Rosana Souza
de Mello Perez, Renata
Chindamo, Maria Chiara
Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title_full Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title_fullStr Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title_full_unstemmed Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title_short Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil
title_sort liver injury predicts overall mortality in severe covid-19: a prospective multicenter study in brazil
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857099/
https://www.ncbi.nlm.nih.gov/pubmed/33534084
http://dx.doi.org/10.1007/s12072-021-10141-6
work_keys_str_mv AT pozzobonfernandamanhaes liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil
AT perazzohugo liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil
AT bozzafernandoaugusto liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil
AT rodriguesrosanasouza liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil
AT demelloperezrenata liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil
AT chindamomariachiara liverinjurypredictsoverallmortalityinseverecovid19aprospectivemulticenterstudyinbrazil